Efficacy and Safety of Deferasirox (Exjade) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Overall and Austrian/German/Swiss Results from EPIC Trial

M Schmid; A Ganser; U Platzbecker; P Beris; Werner Linkesch; D Habr; G Domokos; O Leismann; N Gattermann

Efficacy and Safety of Deferasirox (Exjade) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Overall and Austrian/German/Swiss Results from EPIC Trial

M Schmid
, A Ganser
, U Platzbecker
, P Beris
, Werner Linkesch
, D Habr
, G Domokos
, O Leismann
, N Gattermann

Medical University Graz

Research output: Contribution to journal › Conference abstract

Original language	English
Journal	Oncology Research and Treatment
Publication status	Published - 2009
Event	Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie 2009 - Heidelberg, Germany Duration: 2 Oct 2009 → 6 Oct 2009

Branches of science

302 Clinical Medicine

Efficacy and Safety of Deferasirox (Exjade) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Overall and Austrian/German/Swiss Results from EPIC Trial
Gattermann, N. (Author) & Linkesch, W. (Author)
2009
Activity: Talk, presentation or poster › Poster

Cite this

@article{ae2ee1547d4148949f94dcb2543d9c80,

title = "Efficacy and Safety of Deferasirox (Exjade) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Overall and Austrian/German/Swiss Results from EPIC Trial",

author = "M Schmid and A Ganser and U Platzbecker and P Beris and Werner Linkesch and D Habr and G Domokos and O Leismann and N Gattermann",

year = "2009",

language = "English",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "S. Karger AG",

note = "Jahrestagung der Deutschen, {\"O}sterreichischen und Schweizerischen Gesellschaften f{\"u}r H{\"a}matologie und Onkologie 2009 ; Conference date: 02-10-2009 Through 06-10-2009",

}

TY - JOUR

T1 - Efficacy and Safety of Deferasirox (Exjade) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Overall and Austrian/German/Swiss Results from EPIC Trial

AU - Schmid, M

AU - Ganser, A

AU - Platzbecker, U

AU - Beris, P

AU - Linkesch, Werner

AU - Habr, D

AU - Domokos, G

AU - Leismann, O

AU - Gattermann, N

PY - 2009

Y1 - 2009

M3 - Conference abstract

SN - 2296-5270

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

T2 - Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie 2009

Y2 - 2 October 2009 through 6 October 2009

ER -

Efficacy and Safety of Deferasirox (Exjade) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Overall and Austrian/German/Swiss Results from EPIC Trial

Branches of science

Activities

Efficacy and Safety of Deferasirox (Exjade) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Overall and Austrian/German/Swiss Results from EPIC Trial

Cite this